For research use only. Not for therapeutic Use.
Lificiguat (CAT: I002226) is a potent and selective soluble guanylate cyclase (sGC) stimulator. It works by enhancing the activity of sGC, an enzyme involved in the production of cyclic guanosine monophosphate (cGMP) in cells. By increasing cGMP levels, lificiguat promotes vasodilation and reduces vascular resistance, leading to improved blood flow. This pharmacological activity makes lificiguat a potential therapeutic option for the treatment of pulmonary hypertension, a condition characterized by high blood pressure in the arteries of the lungs. Lificiguat has undergone clinical trials for this indication and has shown promising results in improving exercise capacity and hemodynamic parameters in patients with pulmonary hypertension.
| Catalog Number | I002226 |
| CAS Number | 170632-47-0 |
| Synonyms | (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol |
| Molecular Formula | C19H16N2O2 |
| Purity | ≥95% |
| Target | Guanylate Cyclase |
| Solubility | DMSO: ≥ 51 mg/mL |
| Storage | Store at RT |
| IC50 | 0.6-1.1 μM(Kd, in the presence of CO) [1] |
| IUPAC Name | [5-(1-benzylindazol-3-yl)furan-2-yl]methanol |
| InChI | InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2 |
| InChIKey | OQQVFCKUDYMWGV-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)C4=CC=C(O4)CO |
| Reference | <p style=/line-height:25px/> |
